SLC1A3 and prostate carcinoma: To further confirm the correlation between aspartate/glutamate uptake capacity and ASNase sensitivity, we used SLC1A3‐deficient MCF7 cells (a breast cancer cell line) and DU145 cells (a prostate cancer cell line), and established two cancer cell lines overexpressing SLC1A3: MCF7‐V5‐SLC1A3 and DU145‐V5‐SLC1A3.